N/A N=11 Hypoglycemia (Low Blood Sugar) and the Heart
Hypoglycemia · Type 2 Diabetes
Primary: Number of Participants With Hypoglycemia (Blood Sugar Level <70 mg/dl — 11 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=29 Naltrexone and Hypoglycemia in Type 1 Diabetes
Type 1 Diabetes · Hypoglycemia Unawareness
Primary: Cerebral Blood Flow — 1.7; 1.3 percentage of signal intensity change
Early Phase 1 N=20 Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 4
Type 2 Diabetes
Primary: Percent Changes in Endothelial Function as Measured by Flow Mediated Dilation by 2D Doppler Ultrasound on Day 2 — 2; 7 percentage of change
N/A N=21 Hypoglycemia and the Mineralocorticoid Receptor
Hypoglycemia
Primary: Change From Baseline in Cardiovascular Autonomic Function — -16.00; -16.59 ms/mmHg
N/A N=12 How Common is Hypoglycaemia in Older People With Diabetes Who Fall?
Diabetes · Hypoglycaemia
Primary: Proportion of Participants With Captured Hypoglycaemia — 3 Participants
N/A N=16 Cognition in Patients With Hypoglycemia, Without Diabetes
Hypoglycemia · Cognition
Primary: Assessment of Immediate Verbal Memory — 50; 48 RAVLT scores on a scale (range 0 to 69) — p=0.90
N/A N=27 Effects of Mild Hypoglycaemia on Cognitive Function in Type 2 Diabetes
Diabetes Mellitus, Type II · Hypoglycemia · Cognitive Change
Primary: Psychomotor Speed — 48.7; 56.6 score on a scale
N/A N=587 Associated Factors in Perioperative Hypoglycemia in Patients With Diabetes
Diabetes · Hypoglycemia
Primary: Hypoglycemia Incidence — 53; 10 participants — p=<0.001
N/A N=22 Hypoglycemia and Autonomic Nervous System Function
Hypoglycemia
Primary: Change in Baroreflex Sensitivity — 2.3; -1.6 ms/mmHg
Phase 2 N=20 Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia
Diabetes Mellitus, Type 1
Primary: Number of Hypoglycemic Events ≥50 mg/dl 15 Minutes AND ≥ 70 mg/dl 30 Minutes After Initial Treatment — 58; 53 Hypoglycemic Events — p=0.99
N/A N=17 Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia
Hypoglycemia
Primary: Glucose (mg/dL) — 56.5; 52.8; 55.0; 52.8 mg/dL
Phase 2 N=20 Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients
Pharmacological Action
Primary: The Frequency of Hypoglycaemic Episodes With Sitagliptin vs Placebo Treatment. — 5.35; 5.72 Hypoglycaemic episodes
N/A N=21 Detecting Neonatal Hypoglycemia Using Real-Time Continuous Glucose Monitoring (CGM)
Neonatal Hypoglycemia
Primary: Sensor-detected Hypoglycemia — 5; 1 events
N/A N=6 Testing Glial Pathways to HAAF in Human Subjects Using Carbon 13 Magnetic Resonance Spectroscopy
Diabetes Complications · Hypoglycemia
Primary: Percent Enrichment of Bicarbonate as Measured by Magnetic Resonance Spectroscopy (MRS) — 61.9 % enrichment — p=0.0053
N/A N=35 Insulin Sensitivity, Impaired Counterregulation, and Glucose Variability
Type 1 Diabetes Mellitus
Primary: Insulin Sensitivity — 3.37*10^-4 1/min per uU/mL
N/A N=4 Use of a Hyperinsulinemic-hypyglycemic Clamp to Study Hypoglycemia: a Method Development Study
Diabetes
Primary: Peak Epinephrine Levels — 609 pg/mL
Phase 2 N=110 GPR119 Agonist for Hypoglycemia in Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Maximal Glucagon Concentration During Hypoglycemia — 19.9; 22.5; 82.7 pg/mL
N/A N=480 Maternal Lifestyle and Neonatal Hypoglycemia
Hyperinsulinemia · Miscarriages · Pregnancy
Primary: Neonatal Hypoglycemia — 3; 15 neonates
N/A N=50 A Cognitive Behavioral Therapy (CBT) Intervention to Reduce Fear of Hypoglycemia in Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: Fear of Hypoglycemia — 54.3; 58.7; 35.29; 49.0 units on a scale
N/A N=14 Impact of Hypoglycaemia in Patients With Diabetes Mellitus Type 2 on Platelet Activation
Diabetes Mellitus With Hypoglycemia · Diabetes Mellitus, Type 2 · Hypoglycemia
Primary: Changes in Platelet Activation Marker Adenosin Diphosphate (%) — 63; 64.4; 64.4; 61.1 percentage of ADP
N/A N=1,069 The OBSTACLE Hypoglycemia Study (MK-0000-158)
Type 2 Diabetes
Primary: Correlation Between HbA1c Values at Week 12 and Hypoglycemia Scores — -0.1215 Correlation coefficient — p=0.0002
N/A N=12 Effect of Medium Chain Fatty Acids on Cognitive Function During Acute Hypoglycemia in Patients With Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Immediate Verbal Memory — 15.85; 17.36; 14.97; 13.28 units on a scale
Phase 2 N=30 Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia
Hypoglycemia
Primary: Serious Adverse Events — 0; 0; 0 events
N/A N=14 Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes.
Type 1 Diabetes
Primary: Glucagon (pg/mL) — 76; 74; 53; 56 pg/mL
N/A N=10 A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes
Type1diabetes
Primary: Hypoglycemia Fear Scale Score (HFS_2) — 21.4; 38.6 units on a scale
N/A N=41 Counter-Regulatory Impairment and the Effect of Microvascular Insulin Transfer in Type 1 Diabetes Mellitus
Diabetes Mellitus, Type 1
Primary: Maximum Epinephrine Response (LBGI Groups) — 495; 217 pg/ml
Phase 2 N=5 CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
Congenital Hyperinsulinism
Primary: Number of Subjects With Clinically Meaningful Reduction in Glucose Infusion Rate (Double-Blind) — 2; 0 Participants
Phase 2 N=16 The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Glycemic Response During Exercise and Early Recovery — 86; 85; 174; 161 mg/dL — p=<0.001
Phase 4 N=28 Sitagliptin and Glucagon Counterregulation
Type 2 Diabetes
Primary: Glucagon Counterregulation to Hypoglycemia — 16.0; 16.5 pmol/l
Phase 2 N=12 Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes
Hypoglycemia
Primary: Serious Adverse Events — 0; 0; 0 participants